vimarsana.com

துறை ஆஃப் மருத்துவ நுண்ணுயிரியல் நோயெதிர்ப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Permanent Hearing Loss Caused by Cancer Drug can be Prevented

Permanent Hearing Loss Caused by Cancer Drug can be Prevented by Karishma Abhishek on  May 15, 2021 at 11:56 PM Specific receptor in cells could serve as a key to prevent permanent hearing loss in childhood cancer survivors who are being treated with the drug cisplatin, as per a study Toll-like receptor 4 is activated by platinum and contributes to cisplatin-induced ototoxicity, at the University Of Alberta Faculty Of Medicine & Dentistry, published in EMBO Reports. Cisplatin is an incredibly effective chemotherapeutic when it comes to treating solid tumours in children, contributing to an 80 per cent overall survival rate over five years. But the problem is its side-effects of

Scientists identify receptor in cells that could be key to preventing cancer drug-induced hearing loss

Scientists identify receptor in cells that could be key to preventing cancer drug-induced hearing loss University of Alberta scientists have identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors who are being treated with the drug cisplatin. The researchers believe by inhibiting the receptor, they may be able to eliminate toxic side-effects from the drug that cause the hearing loss. Cisplatin is an incredibly effective chemotherapeutic when it comes to treating solid tumors in children, contributing to an 80 per cent overall survival rate over five years, according to U of A researcher Amit Bhavsar, an assistant professor in the Department of Medical Microbiology & Immunology. The problem has always been with the side-effects. Nearly 100 per cent of patients who receive higher doses of cisplatin show some degree of permanent hearing loss. The ability to prevent this side-effect would dramatically improve the quality of l

Researchers pinpoint possible way to prevent permanent hearing loss caused by cancer drug

 E-Mail IMAGE: University of Alberta researcher Amit Bhavsar is leading a team that has identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors. view more  Credit: William Au University of Alberta scientists have identified a receptor in cells that could be key to preventing permanent hearing loss in childhood cancer survivors who are being treated with the drug cisplatin. The researchers believe by inhibiting the receptor, they may be able to eliminate toxic side-effects from the drug that cause the hearing loss. Cisplatin is an incredibly effective chemotherapeutic when it comes to treating solid tumours in children, contributing to an 80 per cent overall survival rate over five years, according to U of A researcher Amit Bhavsar, an assistant professor in the Department of Medical Microbiology & Immunology. The problem has always been with the side-effects. Nearly 100 per cent of patients who receive higher

Study reveals how oral antiviral drug works to attack SARS-CoV-2 virus

Study reveals how oral antiviral drug works to attack SARS-CoV-2 virus A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry. The researchers demonstrated the underlying mechanism of action by which the antiviral drug molnupiravir changes the viral genome, a process known as excessive mutagenesis or “error catastrophe.” The polymerase, or replication engine of the virus, mistakes molnupiravir molecules for the natural building blocks required for viral genome replication and mixes them in. It causes the polymerase to make sloppy copies nonsense genomes that are useless and not viable.”

University of Alberta lab reveals how a much-needed oral antiviral drug confuses replication machinery of SARS-CoV-2

Date Time Share University of Alberta lab reveals how a much-needed oral antiviral drug confuses replication machinery of SARS-CoV-2 A University of Alberta virology lab has uncovered how an oral antiviral drug works to attack the SARS-CoV-2 virus, in findings published May 10 in the Journal of Biological Chemistry. The researchers demonstrated the underlying mechanism of action by which the antiviral drug molnupiravir changes the viral genome, a process known as excessive mutagenesis or “error catastrophe.” “The polymerase, or replication engine of the virus, mistakes molnupiravir molecules for the natural building blocks required for viral genome replication and mixes them in,” explained Matthias Götte, professor and chair of the Department of Medical Microbiology & Immunology in the Faculty of Medicine & Dentistry and member of the Li Ka Shing Institute of Virology. “It causes the polymerase to make sloppy copies nonsense genomes that are useless and not viable.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.